Application of dopamine d1 receptor antagonist sch39166 as a drug for the treatment of ocular pathological angiogenesis

A technology of SCH39166 and receptor antagonists, which is applied in the field of new applications of SCH39166, can solve the problems of unsustainable effect, short maintenance time, damage to vision, etc. effect of disease

Active Publication Date: 2021-02-23
WENZHOU MEDICAL UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, traditional treatment methods such as retinal photocoagulation or freezing can inhibit the formation of new blood vessels to a certain extent, but they will also damage part of the vision and the effect itself is not long-lasting and needs to be repeated; the anti-VEGF drugs currently used as the first line, although curative It is worthy of recognition, but there are also problems such as short maintenance time and multiple injections

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of dopamine d1 receptor antagonist sch39166 as a drug for the treatment of ocular pathological angiogenesis
  • Application of dopamine d1 receptor antagonist sch39166 as a drug for the treatment of ocular pathological angiogenesis
  • Application of dopamine d1 receptor antagonist sch39166 as a drug for the treatment of ocular pathological angiogenesis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0016] SCH39166 inhibits retinal angiogenesis in oxygen-induced retinal injury

[0017] Littermate C57BL / 6 mice were fed in a 75% hyperoxic environment for 5 days, then moved to a normal oxygen environment on P12 and continued to be fed. From P12, intraperitoneal administration was started, and samples were collected until P17. In the relative hypoxic phase, the SCH39166 drug treatment group had a significantly increased retinal non-perfusion area compared with its solvent DMSO control group (DMSO vs SCH: 13.71% ± 2.64% vs 18.73% ± 3.56%, P = 0.0111, independent t- test), while the area of ​​pathological neovascularization was significantly reduced (DMSO vs SCH39166: 4.40% ± 1.24% vs 2.29% ± 0.83%, P = 0.0030, independent t-test) ( figure 1 ). demonstrated that DRD1 antagonists inhibited pathological neovascularization during the relatively hypoxic phase of the OIR model.

[0018] SCH39166 inhibits laser-induced choroidal angiogenesis

[0019] C57BL / 6 mice aged 8-10 weeks w...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of a dopamine D1 receptor antagonist SCH39166 in preparation of a medicine for treating ocular pathological angiogenesis. The antagonist can inhibit ocular angiogenesis, has a remarkable effect on neovascularization of retinas, corneas and choroids, and can assist in treating angiogenesis ocular diseases.

Description

technical field [0001] The present invention specifically relates to the technical field of new uses of SCH39166, in particular to the application of dopamine D1 receptor antagonist SCH39166 in the preparation of drugs for treating ocular pathological angiogenesis. Background technique [0002] Ocular neovascularization includes retinal neovascularization, corneal neovascularization and choroidal neovascularization. Retinal neovascularization is common in diabetic retinopathy, retinopathy of prematurity, central retinal vein occlusion, and neovascular glaucoma; choroidal neovascularization is common in age-related macular degeneration and pathological myopia. Angiogenesis is normally in a state of dynamic balance under the regulation of pro-angiogenic and anti-angiogenic factors, but in an environment of ischemia, hypoxia or inflammation, this balance will be broken and angiogenesis will be promoted. Pathological angiogenesis of the eye, especially the aforementioned retina...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/55A61P27/02
CPCA61K31/55A61P27/02
Inventor 周翔天杨景雷杨莉
Owner WENZHOU MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap